• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Asp594Asn (c.1780G>A); ClinVar=VCV000044813; Zygosity=Unspecified (PubMed=23658559).
  
• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Asn1112fs; Zygosity=Unspecified (PubMed=32567790).
  
• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Gln2582Ter (c.7744C>T); Zygosity=Unspecified (PubMed=32567790).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
  

PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113
Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S., Finlay G.J., Shelling A.N., Baguley B.C.
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Front. Genet. 4:66.1-66.6(2013)

PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249
Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J., Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S., Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: a valuable model for studying the impact of genetic diversity in melanoma.
Pigment Cell Melanoma Res. 34:136-143(2021)